Catalyst Biosciences (CBIO) Earning Somewhat Positive Media Coverage, Report Shows

Media stories about Catalyst Biosciences (NASDAQ:CBIO) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catalyst Biosciences earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.8886840581909 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Tuesday, January 2nd. B. Riley set a $19.00 price target on shares of Catalyst Biosciences and gave the company a “buy” rating in a report on Monday, December 18th.

Catalyst Biosciences (NASDAQ CBIO) traded up $0.20 during mid-day trading on Friday, reaching $15.13. 105,134 shares of the company’s stock were exchanged, compared to its average volume of 320,969. Catalyst Biosciences has a one year low of $3.11 and a one year high of $18.88. The company has a market capitalization of $87.96, a PE ratio of -1.15 and a beta of 1.86.

TRADEMARK VIOLATION NOTICE: “Catalyst Biosciences (CBIO) Earning Somewhat Positive Media Coverage, Report Shows” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Insider Buying and Selling by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply